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The value of genetic testing for 
inherited retinal disease caused 
by mutations in the ABCA4 gene 
in South Africans
To the Editor: Gene-based therapies for inherited retinal 
degenerative diseases (RDDs) have gained momentum 
in the past 5 years, and there are currently several early-
stage clinical trials underway[1] that have the potential 
to intervene in disease processes and provide clinical 
benefit to patients. However, knowledge of a patient’s 
specific underlying genetic mutation(s) is a prerequisite 
for participation in these trials. Identification of the 
mutations in patients with RDDs is challenging and 
costly; there are more than 200 genes associated with 
RDDs, and each can carry hundreds of potential 
mutations. Finding the one or two mutations responsible 
for the RDD in a patient is daunting, so the best 
candidate gene to screen is often determined by the 
clinical manifestations of the disease and the inheritance 
pattern observed.
Stargardt disease (STGD) is a macular degeneration 
that occurs in childhood, resulting in a profound loss 
of central vision and severely reduced visual acuity. 
Autosomal recessive STGD is frequently caused by seven 
specific mutations of the ABCA4 gene in South African 
whites, particularly those of Afrikaner ancestry.[2] A 
‘founder effect’ describes when a mutation occurs at a 
comparatively high frequency in a certain population, 
because that population has arisen from a small number 
of ancestors (or founders). Several inherited diseases 
occur in Afrikaners as a result of founder mutations, e.g. 
variegate porphyria and familial hypercholesterolaemia. 
We previously reported that 4.8% of Afrikaners are 
unaffected carriers of one of the seven mutations of 
the ABCA4 gene.[2] This gene has also been implicated 
in other more severe recessive RDDs, termed ABCA4-
related retinopathies (AARs). Recessive genetic disorders 
occur when both the parents are carriers of one mutated 
allele of the ABCA4 gene, with their other healthy allele 
compensating, and preventing disease. For the disease 
to manifest, a child must by chance have inherited two 
mutated alleles of the ABCA4 gene, one from the father 
and one from the mother. In order to confirm a genetic 
diagnosis for the recessive RDD, two mutations in 
ABCA4 must therefore be identified in the patient with 
visual impairment.
The aim of a recent study was to determine whether a 
locally developed test for the seven common mutations, 
called ‘Quick 7’ (which provides a genetic diagnosis, i.e. identification 
of both mutations, in 40% of Afrikaner patients with STGD[2]), could 
be effective in screening South Africans with other AARs, such as 
cone-rod dystrophy (CRD), retinitis pigmentosa (RP), and fundus 
flavimaculatis (FFM). Twenty patients with CRD, 4 with FFM and 40 
with RP were screened, and although the test provided a diagnosis 
for 25% of patients with FFM and 10% of those with CRD, it was 
ineffectual in the diagnosis of RP. The vast majority of the patients 
in this cohort were white (79.7%). Although the number of patients 
screened is small, the trend observed supports a previously proposed 
model[3] whereby the ‘severity’ of the gene defect is proportional to 
the severity of the disease: if the combination of the two mutations 
is ‘severe’, the disease will manifest more severely, e.g. RP; if the 
combination of the two mutations in the gene is milder, the disease 
manifestation will be milder, e.g. STGD or FFM. Our finding that 25% 
of CRD patients carry only one of the seven mutations indicates that 
their (as yet unfound) second mutation is more severe. Furthermore, 
only one RP patient had a partial result, suggesting that for this AAR, 
both mutations are severe. In summary, it appears that the seven 
common mutations are more likely to cause relatively mild disorders 
such as STGD and the clinically similar FFM. Different, more severe 
mutations are probably involved in CRD and RP. Therefore, while 
this ‘Quick 7’ assay (requested via the National Health Laboratory 
Service) is valuable and effective for the diagnosis of STGD, it should 
not be offered for other AARs, which are likely to be caused by a 
different spectrum of mutations.
The clinical manifestations of RDD may overlap with each other or 
change with disease progression. Patients may therefore find themselves 
being given different clinical diagnoses and prognoses over time, which 
may be confusing and frustrating, whereas the genetic diagnosis remains 
unequivocal. A confirmed genetic diagnosis also allows testing of the 
extended family, providing clearer risks for individuals and enabling 
life planning and decisions on reproductive options. For those who 
do not carry the family mutations, the fear of potentially developing 
the familial visual impairment can be eliminated. For those affected by 
the disease associated with the ABCA4 mutations, there is additional 
information that can be provided to assist with clinical management. 
Animal studies have shown that high doses of vitamin A (which is 
sometimes prescribed indiscriminately for patients with RDDs) and 
light exposure may exacerbate vision loss when the ABCA4 protein is 
not functioning properly.[4,5] These patients can be cautioned to avoid 
excessive vitamin A supplementation and to wear appropriate protective 
sunglasses in bright light, in order to preserve their vision. This advice 
does not necessarily apply to other RDDs with different underlying 
genetic defects. Finally, to date our research has resulted in the genetic 
diagnosis of more than 160 families with ABCA4 mutations, who are 
now eligible to participate in or benefit from StarGen treatment, the 
ABCA4-gene replacement therapy trials currently in progress.[6]
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